The European Genomic Medicine Consortium (EGMEDC)

Accelerating the Clinical Translation of CRISPR and Genetic Medicines Across Europe

Who we are

The European Genomic Medicine Consortium (EGMEDC) is a pan-European, non-profit initiative convened by CRISPR Medicine News (CMN).

------

Our Mission

Our mission is to unite and empower clinical, academic, regulatory, and industry stakeholders to advance the development and delivery of CRISPR-based and related genetic therapies across Europe.

By aligning these efforts, we aim to establish a coordinated, ethical, and sustainable ecosystem for the clinical translation of genomic medicines - ensuring timely, safe, and equitable access for patients.

------

Strategic Aims

1. Clinical Coordination and Implementation:
   • Aligning cross-border trials, data sharing, and long-term monitoring (CMN Trial Database).
2. Infrastructure Mapping and Creation:
   • Connect Europe's fragmented screening, gene and cell therapy capabilities and implementing joint clinical-grade tools and protocols (first meeting of Europe´s genomic medicine infrastructures will take place during the CRISPRMED26 Satellite meetings).
3. Policy & Regulation:
   • Promote the harmonization of ethical frameworks, health technology assessment (HTA), and European Medicines Agency (EMA) regulatory pathways.
4. Access & Reimbursement:
   • Support scalable and fair access models for genomic medicines across European states.
5. Industry + Public Collaboration:
   • Bridging biotech, academic networks, national programs, and European initiatives to accelerate innovation and translation.
6. Annual Convening Power:
   • EGMEDC´s annual meeting will be achored at CRISPRMED, Europe’s leading genomic medicine conference, held in Copenhagen

------

"Learn - Innovate - Access"

Supporters (early stage)

The European Genomic Medicine Consortium (EGMEDC) is currently in the early development phase. The following organisations have expressed non-binding interest in supporting the initiative and contributing to its emerging structure. Their potential roles reflect areas of alignment and strategic interest, and will be further defined during the formalisation of the consortium. This list will be updated every week.

• Industry: Bayer, Germany / Chiesi, Italy
• Academic / Clinical: Amsterdam UMC, Netherlands / CCIT-DK, Denmark // (Imagine Institute, France / UniKlinik Freiburg, Germany / SJD, Spain...)
• Dissemination Platform: CRISPR Medicine News, CMN - CMN will host quarterly interviews with EGMEDC members to share insights and updates from across the consortium
• Data Intelligence & Infrastructure: A monthly report from the updated version of the CMN Trial Database 1.0 will be made available to EGMEDC members, supporting accessibility, data integration and transparency across participating organisations and companies
• Launch Platform / Annual Meeting: The official launch of EGMEDC will be at the CRISPRMED26 Conference, April 13th 2026, Copenhagen, Denmark
• Legacy Partner: Copenhagen Legacy Lab, CLL - supports the long-term preservation and dissemination of outputs emerging from EGMEDC, serving as a potential anchor point for sustainability and institutional memory
• Innovation: The EGMEDC Secretariat will be based in the Innovation District Copenhagen, IDC, a leading ecosystem for health and life science innovation
• Governance / Compliance Partners: Grant Thornton & Lund Elmer Sandager

Advisory Board

• Pascale BERTHET, Cell'Ectiv Consulting, France
• Cecilia Jimenez Mallebrera, PhD, Research Director, Neuromuscular Unit, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu Barcelona, Spain
• Dr. Sam Ringle, Regulatory Affairs Consultant, Germany
• Henri van de Vrugt, PhD, Advisor to the European Genomic Medicine Consortium, Bio Avenues, Utrecht, the Netherlands